Results 131 to 140 of about 66,268 (303)

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg   +5 more
wiley   +1 more source

Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D).
Rakesh Sahay   +22 more
wiley   +1 more source

Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed‐Dose Titration of Weekly Insulin Efsitora in Insulin‐Naïve Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the QWINT‐1 phase 3 Trial, once‐weekly insulin efsitora alfa (efsitora) administered using an innovative fixed‐dose regimen demonstrated noninferior HbA1c reduction versus once‐daily insulin glargine U100 (glargine) over 52 weeks in insulin‐naïve adults with type 2 diabetes.
Lisa Connery   +9 more
wiley   +1 more source

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim   +5 more
wiley   +1 more source

Efecto inhibitorio de un extracto acuoso de las hojas de Allophylus cominia (L.) Sw sobre las proteínas tirosina fosfatasa 1B y dipeptidil peptidasa IV [PDF]

open access: yes, 2014
Introduction: Allophylus cominia (L.) Sw is a Cuban medicinal plant used by traditional medicine for the treatment of diabetes with unknown mechanisms of action.
L. Harvey, Alan   +3 more
core  

Dipeptidyl Peptidase 4 Inhibitors: Therapeutic Options

open access: yesEffective Pharmacotherapy
Dipeptidyl peptidase 4 inhibitors are a new innovative class of glucose-lowering drugs. The drugs belong to the group of incretin mimetics, prolonging the action of their own incretins. Since 2007, the list of proposed dipeptidyl peptidase 4 inhibitors has expanded significantly and significant experience in their use has accumulated.
S.V. Podachina, I.V. Soloviova
openaire   +1 more source

Understanding how enzymes work: the journey to ensemble–function studies

open access: yesThe FEBS Journal, EarlyView.
For decades, structure–function has dominated biochemistry. Structures are highly valuable, yet more is needed to achieve a quantitative understanding of biomolecular function, because function emerges from an ensemble of states, rather than a static structure. We describe an ensemble–function framework applied to quantitatively dissect serine protease
Daniel Herschlag, Siyuan Du
wiley   +1 more source

Home - About - Disclaimer - Privacy